"Yesterday, the Food and Drug Administration (FDA) approved Novo Nordisk 's ( ) Wegovy weight-loss pill, the first of its kind. This once-daily tablet uses the same active ingredient - semaglutide - as the injectable Wegovy and Ozempic, but in a higher 25 mg dose to achieve comparable efficacy despite lower absorption because it is taken orally. This approval differs from the weekly Wegovy injection because it offers needle-free convenience for patients averse to injections."
"In Novo's OASIS 4 trial, participants lost an average of 16.6% of body weight over 64 weeks, similar to the results seen with the injectable Wegovy. The pill must be taken in the morning on an empty stomach, 30 minutes before eating or drinking, to protect the formulation from breaking down in the stomach. An oral formulation, however, dramatically broadens the addressable market for weight-loss therapies. Many patients avoid injectables due to needle phobia, administration complexity, or lifestyle preferences."
The FDA approved an oral Wegovy pill containing semaglutide at a 25 mg dose to provide comparable efficacy to injectable GLP-1 therapies despite lower absorption. The tablet is taken once daily on an empty stomach, 30 minutes before eating or drinking, to prevent stomach breakdown. In the OASIS 4 trial, participants lost an average 16.6% of body weight over 64 weeks, similar to injectable Wegovy results. Oral dosing removes needle barriers, broadening the addressable obesity-treatment market and improving adherence for patients who avoid injections. Oral GLP-1 options could add substantial revenue to an already multibillion-dollar market.
Read at 24/7 Wall St.
Unable to calculate read time
Collection
[
|
...
]